<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7462660\results\search\testTrace\results.xml">
  <result pre="indicating that ACE2-expressing cells are the primary targets for SARS-CoV" exact="infection" post="in vivo in humans. High levels of PICs were"/>
  <result pre="size 4. Gao C, et al. doi: 10.1093/eurheartj/ehaa433. Association between" exact="treatment" post="of hypertension and mortality of patients with COVID-19. 2877"/>
  <result pre="mitigate the risk; and (iii) will RAASi affect risk of" exact="infection" post="when equally exposed to the virus? 5. Gnavi R,"/>
  <result pre="diseases/diabetes (CDD). 316 HY and 171 CDD cases of COVID-19" exact="infection" post="matched with 1580 and 855 controls. No reason to"/>
  <result pre="to explore whether RAAS therapy increases the risk of SARS-CoV-2" exact="infection" post="Small sample size 6. Guo T, et al. doi:"/>
  <result pre="Small number of patients taking ACEIs/ARBs. Uncertain whether the ACEi/ARB" exact="treatment" post="was maintained throughout hospitalization. 9. Mancia G, et al."/>
  <result pre="ACEi/ARB in patients with COVID-19 than controls attributed to higher" exact="prevalence" post="of cardiovascular disease. ACEi/ARB did not affect the risk"/>
  <result pre="al. doi: 10.1101/2020.04.09.20059964. Association between demographic and clinical characteristics and" exact="testing" post="positive for COVID-19, and among COVID-19+ subsequent hospitalization and"/>
  <result pre="active in care, 585/3789 (15.4%) tested COVID-19+. Racial differences in" exact="testing" post="positive for COVID-19 underestimate of general population. Risk of"/>
  <result pre="admission. 14. Reynolds HR, et al. doi: 10.1056/NEJMoa2008975. Association between" exact="treatment" post="with ACEi, ARB, BBs, CCBs, or thiazides and likelihood"/>
  <result pre="16. Rossi PG, et al. doi: 10.1101/2020.04.13.20063545. Age- and sex-specific" exact="prevalence" post="of COVID-19 and its prognostic factors. 2653 symptomatic patients"/>
  <result pre="17. Tedeschi S, et al. doi: 10.1093/cid/ciaa492. Investigation of whether" exact="treatment" post="with RASi, has an impact on in-hospital mortality in"/>
  <result pre="current standards of care should be systematically subjected to such" exact="testing" post="[21]. However, some questions about therapy cannot wait for"/>
  <result pre="result, in the guidelines, beta-blockers are not recommended for the" exact="treatment" post="of HFpEF. These are just few examples that OSs"/>
  <result pre="had proved lifesaving in the pre COVID-19 era; (h) RCTs" exact="testing" post="the efficacy and safety of RAASi in the COVID-19"/>
  <result pre="cotransporter 2 inhibitors (SGLT2i), a new drug class approved for" exact="treatment" post="of diabetes, have been shown to significantly reduce atherosclerotic"/>
  <result pre="COVID-19. The important issue that the outcome of a viral" exact="infection" post="may be related to therapy provided for another underlying"/>
  <result pre="lacking and new ones emerge daily regarding mechanisms, clinical characteristics," exact="treatment" post="options, and outcomes for COVID-19. Steadfast use of ACEi/ARB"/>
  <result pre="their pharmacokinetic and pharmacodynamic effects. The possibility that a viral" exact="infection" post="may alter drug effects and consequently the final disease"/>
  <result pre="MasHypertension20187251072107510.1161/HYPERTENSIONAHA.118.1091830354821 6.JiaHPLookDCShiLHickeyMPeweLNetlandJFarzanMWohlford-LenaneCPerlmanSMcCrayPBJrACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epitheliaJ Virol20057923146141462110.1128/JVI.79.23.14614-14621.200516282461 7.HeurichAHofmann-WinklerHGiererSLiepoldTJahnOPohlmannSTMPRSS2"/>
  <result pre="COVID-19. J Autoimmun:102463. 10.1016/j.jaut.2020.102463 15.TomasoniDItaliaLAdamoMInciardiRMLombardiCMSolomonSDMetraMCOVID 19 and heart failure: from" exact="infection" post="to inflammation and angiotensin II stimulation. Searching for evidence"/>
  <result pre="what it isn'tBMJ19963127023717210.1136/bmj.312.7023.718555924 28.PonikowskiPVoorsAAAnkerSDBuenoHClelandJGFCoatsAJSFalkVGonzalez-JuanateyJRHarjolaVPJankowskaEAJessupMLindeCNihoyannopoulosPParissisJTPieskeBRileyJPRosanoGMCRuilopeLMRuschitzkaFRuttenFHvan der MeerP2016 ESC guidelines for the" exact="diagnosis" post="and treatment of acute and chronic heart failureRev Esp"/>
  <result pre="isn'tBMJ19963127023717210.1136/bmj.312.7023.718555924 28.PonikowskiPVoorsAAAnkerSDBuenoHClelandJGFCoatsAJSFalkVGonzalez-JuanateyJRHarjolaVPJankowskaEAJessupMLindeCNihoyannopoulosPParissisJTPieskeBRileyJPRosanoGMCRuilopeLMRuschitzkaFRuttenFHvan der MeerP2016 ESC guidelines for the diagnosis and" exact="treatment" post="of acute and chronic heart failureRev Esp Cardiol (Engl"/>
 </snippets>
</snippetsTree>
